Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm, Residual × Calcium × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 9 Osteoporosis 7 Colorectal Neoplasms 4 Bone Diseases, Metabolic 4 Vitamin D Deficiency 2 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pain 2 Lymphoma 2 Leukemia 2 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Polycystic Ovary Syndrome 1 Pancreatic Neoplasms 1 Paclitaxel-induced Neuropathy 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 1 1 Kidney Neoplasms 1 Head and Neck Neoplasms 1 Dwarfism, Pituitary 1 Disease Progression 1 Depression 1 Colonic Polyps 1 Carcinoma, Transitional Cell 1 Body Weight Changes 1 Arthralgia 1

Interventions

Cyclophosphamide 20 blinatumomab 16 fludarabine 13 Cytarabine 13 Azacitidine 12 venetoclax 10 fludarabine phosphate 9 Rituximab 7 Dexamethasone 7 Methotrexate 6 Lenalidomide 6 Daunorubicin 6 daratumumab 4 Whole-Body Irradiation 4 Vincristine 4 Mercaptopurine 4 Melphalan 4 Idarubicin 4 Etoposide 4 obinutuzumab 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Cladribine 3 Busulfan 3 Asparaginase 3 tislelizumab 2 tisagenlecleucel 2 thymoglobulin 2 pembrolizumab 2 palbociclib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00172068 2009-12-23

MRD-1

Novartis

Phase 2 Terminated

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡